What Are Benzodiazepines?

Benzodiazepines produce physical dependence with continued use, and that dependence develops within weeks at ordinary prescribed doses.

This page covers what benzodiazepines are, what they treat, and how dependence develops at prescribed doses. It also covers why withdrawal carries seizure risk and why a supervised taper is the standard of care.

Key Takeaways

• Benzodiazepine withdrawal and alcohol withdrawal are both life-threatening withdrawal syndromes. Both act through GABA and both can produce seizures.
• Physical dependence develops within weeks at prescribed doses. It does not require misuse, escalation or any illicit source.
• The 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering, led by the American Society of Addiction Medicine with nine partner societies, states that people taking benzodiazepines for longer than one month should not stop abruptly.
• A taper must be individualized. There is no single correct rate, and a schedule that suits one person will be too fast for another.
• Benzodiazepines combined with opioids substantially raise the risk of fatal respiratory depression, because both suppress the drive to breathe.

What are benzodiazepines and how do they work?

Benzodiazepines are medications that bind to the GABA-A receptor and increase the effect of GABA, the brain's main inhibitory neurotransmitter. Enhanced GABA signalling reduces neuronal excitability, which produces sedation, reduced anxiety, muscle relaxation and raised seizure threshold.

Benzodiazepines occupy an unusual position in medicine. Benzodiazepines work quickly and work well, which is why they remain among the most widely prescribed medications in the United States. Benzodiazepines also produce physical dependence on a timescale measured in weeks rather than years, and they do so in patients taking them exactly as directed.

That combination creates a particular kind of harm. A person follows every instruction they were given, never escalates the dose, never obtains the medication from anyone but a pharmacist, and still finds that stopping is medically dangerous. Dependence here is not a consequence of misuse. Dependence here is a predictable pharmacological outcome of appropriate use.

GABA is the brake in the central nervous system. Benzodiazepines do not act as a brake themselves. They increase the effectiveness of the brake that is already there, which is why they are comparatively safe on their own and considerably less safe in combination with other depressants.

The class divides usefully by duration of action, which determines both clinical use and withdrawal behavior.

Duration matters more than potency for understanding what happens on stopping. Short-acting benzodiazepines leave the body quickly, so the drop in GABA support is abrupt and withdrawal begins sooner and hits harder. Long-acting benzodiazepines decline gradually, which is precisely why a long-acting agent is often substituted before a taper begins.

Benzodiazepines share their mechanism with alcohol, which also enhances GABA signalling. That shared mechanism is why the two withdrawal syndromes resemble each other and why they carry the same seizure risk. It is also why benzodiazepines are the standard treatment for alcohol withdrawal, described on the page on alcohol addiction, its signs, effects and withdrawal.

What are benzodiazepines prescribed for?

Benzodiazepines are prescribed for anxiety disorders, panic disorder, insomnia, seizure disorders and status epilepticus, muscle spasm, procedural sedation, and the management of alcohol withdrawal. Most guidelines now recommend short-term rather than continuous use.

These are legitimate and often highly effective indications. A benzodiazepine can stop a seizure, break a panic attack and prevent delirium tremens, and in each of those situations it does something no other medication class does as reliably or as quickly.

Prescribing guidance has nevertheless shifted substantially over the past two decades, and the reason is duration rather than efficacy. Benzodiazepines were once prescribed continuously for anxiety and insomnia over years. Current guidance favors the shortest effective course, because tolerance to the anxiolytic and hypnotic effects develops while the dependence does not resolve.

One combination warrants specific mention because it drives mortality. Benzodiazepines taken alongside opioids substantially raise the risk of fatal respiratory depression, since both suppress the brainstem drive to breathe through different mechanisms. This combination appears frequently in overdose deaths, and it is a reason prescribers avoid co-prescribing where alternatives exist.

How does benzodiazepine dependence develop at prescribed doses?

Benzodiazepine dependence develops because the brain compensates for enhanced GABA signalling by reducing GABA-A receptor sensitivity and increasing excitatory glutamate activity. That adaptation occurs within weeks at prescribed doses and does not require escalation or misuse.

The adaptation is a homeostatic response rather than a failure of self-control. Sustained enhancement of the brain's inhibitory system prompts the brain to restore its own balance by turning inhibition down and excitation up. While the medication is present, the two roughly cancel. Remove the medication and the compensations remain, leaving excitation unopposed.

Two distinct things are being described here, and conflating them causes real harm:

• Physical dependence is a physiological adaptation producing withdrawal on cessation. It develops in almost everyone taking benzodiazepines regularly for more than a few weeks, including patients using them exactly as prescribed.
• Benzodiazepine use disorder is the DSM-5-TR diagnosis, requiring behavioral features such as loss of control, craving and continued use despite harm. It develops in a minority.

A patient who has taken a prescribed benzodiazepine nightly for six months is physically dependent and in most cases does not have a use disorder. Telling that patient they have an addiction is inaccurate. Telling them they can therefore stop whenever they like is dangerous. Both statements are made regularly, and both are wrong.

Timescale is the fact most often missed. Meaningful dependence develops within weeks, not years, which is why guidance frames a month of continuous use as the point at which abrupt discontinuation stops being safe.

Why is benzodiazepine withdrawal dangerous?

Benzodiazepine withdrawal is dangerous because the brain has downregulated inhibitory GABA signalling and upregulated excitatory glutamate signalling. Removing the medication leaves excitation unopposed, and the resulting hyperexcitability produces seizures and, in severe cases, delirium.

This is the same mechanism that makes alcohol withdrawal dangerous, and benzodiazepine withdrawal and alcohol withdrawal are both life-threatening withdrawal syndromes. Opioid withdrawal is severe and rarely fatal. Stimulant withdrawal is psychologically punishing and physically safe. Benzodiazepines sit in the small category requiring medical management for physical safety.

Withdrawal symptoms span three groups. Rebound symptoms are the return of the original complaint, frequently more intensely than before. Physical symptoms include tremor, sweating, palpitations, muscle pain, headache and heightened sensitivity to light and sound. Neurological and psychiatric symptoms include severe anxiety, panic, perceptual disturbance, depersonalization, delirium and seizures. Those three groups make up the full range of benzodiazepine withdrawal symptoms.

Onset tracks the half-life of the medication. Withdrawal from short-acting agents such as alprazolam typically begins within 24 hours and is often abrupt, which is covered on the page on Xanax and Ativan withdrawal. Withdrawal from long-acting agents such as diazepam may not begin for several days and develops more gradually.

A protracted withdrawal syndrome follows the acute phase in a subset of people, with anxiety, insomnia, perceptual disturbance and cognitive difficulty persisting for months. This is one reason the rate of the taper matters as much as the fact of it.

Why must benzodiazepines be tapered rather than stopped?

Benzodiazepines must be tapered because a gradual dose reduction allows GABA-A receptor sensitivity to recover in step with the falling dose, which prevents the hyperexcitable state that produces seizures. Abrupt cessation removes the medication faster than the brain can readapt.

The 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering, developed by the American Society of Addiction Medicine with nine partner societies and published in the Journal of General Internal Medicine, states the position directly. Benzodiazepines should not be discontinued abruptly in patients likely to be physically dependent. Patients taking them for longer than one month should have the dose tapered gradually under clinical supervision rather than stopping.

The guideline sets out 5 principles for a taper:

• Individualizing the schedule to the patient, their dose, their duration of use and their response, rather than applying a fixed protocol
• Assessing risks and benefits continuously through the taper, rather than only at the decision to begin
• Sharing the decision with the patient, since a taper the patient has not agreed to is a taper that tends to fail
• Slowing or pausing the reduction when withdrawal symptoms become intolerable, rather than pressing on to a schedule
• Offering psychosocial support alongside the taper, particularly for the anxiety the medication was originally prescribed to treat

There is no single correct taper rate. A rate that one person tolerates comfortably will be too fast for another taking the same dose for the same duration, and the guideline is explicit that individualization rather than protocol adherence is the standard.

Where a taper cannot be managed safely in the community, it moves into a supervised setting.

How is benzodiazepine dependence treated?

Benzodiazepine dependence is treated with a medically supervised taper, frequently after substituting a long-acting benzodiazepine for a short-acting one, combined with treatment for the underlying condition the medication was prescribed for.

Substitution is often the first step. Converting a short-acting benzodiazepine such as alprazolam to an equivalent dose of a long-acting agent such as diazepam produces smoother blood levels and removes the inter-dose withdrawal that makes short-acting agents difficult to reduce. The taper then proceeds from the long-acting medication.

Setting is determined by risk. A stable patient on a modest dose with good support tapers as an outpatient over months. A person on a high dose, using multiple substances, with a history of withdrawal seizures or with significant medical or psychiatric comorbidity requires inpatient withdrawal management. The American Society of Addiction Medicine designates medically monitored inpatient withdrawal management as Level 3.7, providing 24-hour nursing with daily physician availability.

Treating the underlying condition is what determines whether the taper holds. Most people were prescribed a benzodiazepine for anxiety or insomnia, and those conditions do not resolve because the medication stopped. Cognitive behavioral therapy for insomnia and for anxiety has a strong evidence base and does not carry dependence risk, and it addresses the problem the medication was managing.

Clinicians score benzodiazepine withdrawal with the Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B), the 22-item instrument published by Busto and colleagues, which bands severity from mild to very severe. Heather Ashton's manual, Benzodiazepines: How They Work and How to Withdraw, remains the reference protocol for substitution to a long-acting benzodiazepine and stepwise reduction.

Adjunct medication is investigational rather than established. Dueno and colleagues reviewed pregabalin and anti-seizure medications used to support discontinuation and found inconsistent results on low-quality evidence. Flumazenil infusion remains controversial, because the benefit is uncertain and the adverse event risk rises. Neither is a substitute for a supervised taper.

Polysubstance use changes the calculation substantially. Benzodiazepines are frequently used alongside alcohol or opioids, and combined alcohol and benzodiazepine dependence produces a withdrawal in which both GABA-mediated syndromes overlap. That combination is managed as an inpatient.

Frequently asked questions

Sources

1. American Society of Addiction Medicine and nine partner societies (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits, Journal of General Internal Medicine. Tapering principles, the one-month threshold, and the recommendation against abrupt discontinuation.
2. American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Sedative, hypnotic or anxiolytic use disorder criteria, and the distinction from physical dependence.
3. American Society of Addiction Medicine. The ASAM Criteria. Definitions of levels of care, including Level 3.7 medically monitored intensive inpatient services.
4. US Food and Drug Administration (2020). Boxed warning update for benzodiazepines covering abuse, dependence, withdrawal reactions, and the risks of co-prescription with opioids.
5. Busto, U. E. et al. (1989). A clinical scale to assess benzodiazepine withdrawal, Journal of Clinical Psychopharmacology, 9(6), 412-416. The CIWA-B instrument.
6. Ashton, C. Heather (2002). Benzodiazepines: How They Work and How to Withdraw, University of Newcastle upon Tyne. The Ashton Manual, the reference tapering protocol.
7. Dueno, M. R. et al. (2026). Utilization of adjunctive anti-seizure medications to facilitate chronic benzodiazepine discontinuation, The Mental Health Clinician, 16(3), 141-149. Evidence quality for pregabalin and anti-seizure adjuncts.